Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis

ILARIA CAVAZZANA, ANGELA CERIBELLI, MARA TARABORELLI, MICAELA FREDI, GARY NORMAN, ANGELA TINCANI, MINORU SATOH and FRANCO FRANCESCHINI
The Journal of Rheumatology October 2011, 38 (10) 2180-2185; DOI: https://doi.org/10.3899/jrheum.110167
ILARIA CAVAZZANA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ilariacava@virgilio.it
ANGELA CERIBELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARA TARABORELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICAELA FREDI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GARY NORMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGELA TINCANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MINORU SATOH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCO FRANCESCHINI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To analyze the prevalence, associations, and fine specificity of autoantibodies to primary biliary cirrhosis (PBC)-associated antigens (MIT3, Sp100, and gp210) in a cohort of Italian patients with systemic sclerosis (SSc).

Methods. Sera samples from 201 patients with SSc were tested for antibodies to MIT3, gp210, and Sp100 by ELISA (the PBC screen). Anti-MIT3-positive sera were studied for IgG or IgA isotypes. All sera were analyzed by indirect immunofluorescence on HEp-2 cells and on rodent kidney/stomach/liver tissue sections in order to detect antinuclear and antimitochondrial antibodies (AMA). SSc was selected by American College of Rheumatology criteria and classified based on LeRoy’s criteria.

Results. Forty-three (21.4%) sera samples were positive for PBC screen antibodies. Anti-MIT3 antibodies were detected in 36 samples, anti-Sp100 in 5, and anti-gp210 in 1 sample. The other 3 PBC screen-positive samples showed no specificity for the single antigens. PBC screen-positive patients more frequently showed a limited cutaneous SSc subtype (p = 0.04), anticentromere antibodies (ACA; p = 0.0013), elevated alkaline phosphatase (ALP) (p < 0.0001), PBC (p = 0.002), and AMA (p = 0.008). Teleangiectasia and calcinosis were less frequent in this group of patients. IgG+IgA anti-MIT3-positive patients had higher prevalence of AMA (p = 0.0035), diagnosis of PBC (p = 0.014), and increased ALP (p = 0.039), all considered biochemical markers of severe liver disease.

Conclusion. PBC screen antibodies were detected in 20% of patients with SSc, strongly associated with ACA. ACA+/PBC screen+ patients had higher risk of developing PBC or elevation of ALP.

Key Indexing Terms:
  • PRIMARY BILIARY CIRRHOSIS
  • SYSTEMIC SCLEROSIS
  • ANTICENTROMERE
  • ANTIMITOCHONDRIAL ANTIBODIES
  • ALKALINE PHOSPHATASE

Primary biliary cirrhosis (PBC) is a chronic autoimmune cholestatic liver disease, characterized by slow and indolent progression to liver failure. It can frequently be associated with autoimmune diseases such as Sjögren’s syndrome, autoimmune thyroiditis, and systemic sclerosis (SSc). It has been reported that 2%–3% of cases of SSc have coexisting PBC1,2,3. The serological hallmark of PBC is presence of antimitochondrial antibodies (AMA), detected in about 90% of cases, occurring long before clinical onset of the disease4,5. Nevertheless, AMA do not predict the severity of PBC or any clinical subset of disease6. Antibodies to multiple nuclear dots, including promyelocytic leukemia and Sp100 antigens7, and antibodies recognizing different peptides of nuclear pore complex, such as gp210 or p62, are also currently considered serological markers of the disease8,9 associated with severe prognosis8,9,10,11. Recently, an ELISA has been developed to detect AMA using a combination of 3 mitochondrial antigens: MIT3 (pyruvate dehydrogenase complex, branched chain oxo-acid dehydrogenase complex, and oxo-acid glutarate dehydronase complex), anti-Sp100, and anti-gp21012. The combination of anti-MIT3 and anti-Sp100 has been shown to retain high sensitivity and specificity for a diagnosis of clinically evident PBC in SSc2. The aim of our study was to analyze the prevalence, clinical associations, and the isotype specificity of antibodies to MIT3, Sp100, and gp210 in a cohort of Italian patients with SSc. Considering the diagnosis of PBC as the “gold standard,” we assessed the sensitivity and specificity of anti-MIT3 antibodies.

MATERIALS AND METHODS

Patients

Among 440 consecutive patients with SSc followed at our institution (Rheumatology Unit, Brescia, Italy) since 1983, we analyzed clinical and laboratory data of 201 subjects whose sera were available for autoantibody analysis. All patients gave their informed consent for the study. More than 99% of patients were Caucasians of Italian ancestry. SSc was diagnosed according to the American College of Rheumatology criteria13 and classified according to the LeRoy criteria14 in order to define the different clinical subsets. Patients were routinely evaluated following the standard recommended guidelines15: active interstitial lung disease was diagnosed on high-resolution computer tomography and/or bronchoalveolar lavage findings; pulmonary arterial hypertension (PAH) was defined using Doppler echocardiography, performed at least yearly, as screening test and right heart catheterization as the gold standard, as recommended15. A total of 23 PBC cases were followed in our clinic. Among 201 patients considered in this report, a liver biopsy was performed in 8: a histological diagnosis of PBC was confirmed in 7 cases, and 1 case of hepatitis C virus-related cirrhosis was detected and not considered in the analysis. A diagnosis of PBC was made globally in 8 patients combining laboratory, immunological, and/or histological data according to the European Association for the Study of the Liver Clinical Practice Guidelines16: 6 cases with anti-PBC screen antibodies (histologically confirmed in 5) and 2 cases without anti-PBC screen antibodies. Patients with chronic hepatitis B or C viral infections were excluded. No case of autoimmune hepatitis was diagnosed. All the patients with a clinical/histological diagnosis of PBC were undergoing urso-deoxycholic acid (UDCA) treatment. The Mayo risk score was performed on individual subjects with PBC at time of liver disease diagnosis in order to determine their survival17 and the timing of liver transplantation18. Elevation of alkaline phosphatase (ALP; defined as a value 3-fold higher than normal values) was the best available marker of PBC activity in our cases, as collected from medical records19: elevation of ALP was defined when confirmed in more than 3 consecutive assessments during followup.

Methods

The available sera samples of 201 SSc patients were analyzed by indirect immunofluorescence (IIF) test on HEp-2 cells (Bio-Rad, Hercules, CA, USA) for antinuclear antibodies, including anticentromere (ACA), considered positive at a titer ≥ 1:80. Antiextractable nuclear antigen antibodies, namely those directed to topo-1, Ku, PM/Scl, U1RNP, Ro/SSA, La/SSB, Jo-1, Sm, PCNA, ribosomal P, and Ki/SL antigen, were tested by counterimmunoelectrophoresis, using rabbit thymus and human or porcine spleen extracts as substrates20,21,22. Anti-RNA polymerase III (RNAPIII) antibodies were tested with a commercial ELISA kit (Inova Diagnostics Inc., San Diego, CA, USA). Anti-Th/To antibodies were tested by RNA immunoprecipitation of K562 cell extract, with urea-PAGE and silver staining (Silver Stain Plus; Bio-Rad)23.

AMA were identified by IIF on rodent kidney/stomach/liver tissue sections using anti-human total immunoglobulin antibodies (Kallestad, Chaska, MN, USA), considered positive at titer > 1:20. All the 201 sera were analyzed by ELISA (QuantaLite™ PBC Screen IgG/IgA ELISA, Inova Diagnostics) for antibodies to MIT3, using goat anti-human IgA or anti-human IgG antibodies as secondary antibodies, anti-Sp100, and anti-gp210. All 201 sera were tested by ELISA using a mixture of MIT3, Sp100, and gp210 antigens, called the PBC screen. Positive sera were then tested on individual MIT3, Sp100, and gp210 antigens by ELISA.

Statistical analysis

All the variables were expressed as mean values and SD. The prevalence between groups was compared by Fisher exact test. Student’s t or Mann-Whitney U test was used for comparison of levels/values between groups. Statistical significance was accepted at p < 0.05.

RESULTS

Antibodies to at least 1 of MIT3, gp210, or Sp100 (PBC screen) were found in 21% (43/201) of sera. Anti-MIT3 antibodies were detected in 17.9% (36/201), anti-Sp100 antibodies in 2.5% (5/201: 3 cases as isolated specificity and 2 cases associated with anti-MIT3), and only 1 serum sample was positive for anti-gp210 (0.5%). The other 3 sera were positive for the PBC screen, but showed no specificity for individual antigens and were not included in the analysis.

Clinical data of 40 PBC screen-positive and 158 screen-negative patients are summarized in Table 1. Mean ages at SSc onset, followup, and mortality were similar between groups. The female:male ratio was 12:1 in the PBC screen-positive group compared to the negative group (5.8:1) but the difference was not statistically significant. A diagnosis of PBC was assessed globally in 8 patients: 6 were PBC screen-positive and 2 were PBC screen-negative cases. At the time of PBC diagnosis, patients in both groups showed a low and comparable Mayo risk score. No cases of liver decompensation were detected during followup. A limited cutaneous SSc variant was more common in PBC screen-positive (80%) compared to PBC screen-negative (63%) cases (p = 0.04); however, calcinosis was significantly less frequent (p = 0.012) in the PBC screen-positive group. Elevated ALP (p < 0.0001), PBC (p = 0.0024), and AMA by immunofluorescence (p = 0.008) were associated with the PBC screen-positive group.

View this table:
  • View inline
  • View popup
Table 1.

Clinical and immunological data of 40 patients with SSc screened for PBC antibodies.

The most frequent SSc-related autoantibody in the PBC screen-positive group was ACA (55%), followed by anti-topo-I (20%). ACA showed a significantly higher prevalence in the PBC screen-positive group (p = 0.0013). Anti-U1RNP, anti-Ku, anti-Ro/SSA, and anti-RNAPIII antibodies were found in 1 case each.

Since ACA was twice as prevalent in the PBC screen-positive group compared to the screen-negative group, we examined only ACA-positive patients in order to determine whether this clinical association was due to a different prevalence of ACA (Table 2). The same trend was found (reduced telangiectasia and calcinosis; significant increase of ALP, PBC, and AMA), indicating that the association was not due to a different prevalence of ACA between the groups. In contrast, no differences were found between PBC screen-positive and negative subjects when anti-topo-I-positive patients were considered (data not shown). Indeed, PBC was found in 5 cases of ACA-positive/PBC screen-positive, in 1 case of PBC screen-positive, and in 2 cases without PBC screen or the other SSc-related autoantibodies.

View this table:
  • View inline
  • View popup
Table 2.

Comparison of ACA+/PBC screen-positive (23 cases) and ACA+/PBC screen-negative (43 cases).

Distributions of PBC, prevalence of elevated ALP in SSc, and different SSc-related autoantibodies are illustrated in Table 3 and Figure 1. PBC screen antibodies were more prevalent in the ACA-positive group, compared with the anti-topo-I-positive group (p = 0.068), anti-RNAP III-positive group (p = 0.05), or other autoantiody-positive group (p = 0.036). The diagnosis of PBC was more frequent in the ACA-positive than the anti-topo-I-positive group (p = 0.028). Further, comparing ACA-positive/PBC screen-positive cases with other autoantibody-positive/PBC screen-positive cases, we found more frequent PBC [5/22 (22.7%) vs 1/18 (5.5%)] and PBC and/or ALP elevation [9/22 (40.9%) vs 3/18 (16.7%)] in the former group.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Distribution of primary biliary cirrhosis (PBC) and prevalence of elevated alkaline phosphatase (ALP) in SSc cases with different SSc-related autoantibodies in 201 patients with SSc.

View this table:
  • View inline
  • View popup
Table 3.

PBC screening antibodies and PBC in different SSc-related autoantibodies.

The distribution of different anti-MIT3 isotypes is summarized in Figure 2: isolated IgG anti-MIT3 were found in 16/36 (44.5%) sera samples; isolated IgA anti-MIT3 in 12/36 (33.4%) samples, in 1 case associated with anti-Sp100 antibodies; and IgG+IgA anti-MIT3 in 8/36 (22.3%) samples, in 1 case with anti-Sp100 antibodies. Anti-Sp100 were found in 5 sera samples: in 3 as an isolated specificity; in 2 cases associated with IgG; and in IgG+IgA anti-MIT3 antibodies in 1 case each. Anti-gp210 antibodies were detected in 1 case.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Associations among primary biliary cirrhosis (PBC) and various anti-MIT3 isotype antibodies.

Clinical associations of different anti-MIT3 isotypes are shown in Table 4. Skin ulcers were observed more frequently in patients with isolated IgG anti-MIT3 compared with the IgA anti-MIT3-positive group (p = 0.026). PAH was frequently observed in IgG anti-MIT3-positive cases (31%) and in IgG+IgA anti-MIT3-positive cases (38%) compared with isolated IgA MIT3-positive (p = 0.024 and p = 0.048, respectively). No case of PAH was observed in IgA anti-MIT3-positive, thus this association is specific for IgG class anti-MIT3. The IgG+IgA anti-MIT3 group appeared to be most closely associated with clinical PBC: the IgG+IgA anti-MIT3-positive group showed a more frequent diagnosis of PBC (50%) and a more frequent elevation of serum ALP (62.5%) compared with other groups (p = 0.014 and p = 0.039, respectively). AMA were more frequently detected in IgG+IgA anti-MIT3-positive patients (62.5%) vs isolated IgA (0%) or IgG (13%; p = 0.005 and p = 0.0026, respectively). Within IgG+IgA anti-MIT3-positive patients, ALP elevation was found in 4/5 ACA-positive cases and 1/3 ACA-negative cases. Although diagnosis of PBC was more frequent in IgG+IgA anti-MIT3 cases, we did not observe higher IgM levels in this group, as expected (data not shown).

View this table:
  • View inline
  • View popup
Table 4.

Clinical and laboratory features in 36 patients with positive SSc for anti-MIT3 antibodies.

Anti-MIT3 antibodies by ELISA showed an overall sensitivity and specificity of 75% and 85.4%, respectively, for the diagnosis of PBC, while AMA (by IIF) showed a lower sensitivity (62.5%) and a higher specificity (97.2%).

DISCUSSION

Autoantibodies can be produced in patients years before the clinical onset of disease, as described for anticitrullinated protein antibodies in rheumatoid arthritis or anti-dsDNA in systemic lupus erythematosus24,25. Similarly, AMA is considered a specific autoimmune marker of PBC, produced many years before clinical onset of disease4,5. However, no direct correlation between AMA and disease severity has been described to date. Although found more rarely, anti-Sp100 and anti-gp210 seem to carry a higher risk for more severe and aggressive PBC8,9,10,11. AMA are usually detected using the IIF test on rodent tissue extracts, while anti-Sp100 and anti-gp210 can be detected by line immunoassays on recombinant antigens26 or less readily available tests, such as immunoprecipitation on purified rat liver nuclear membrane as antigen source27. An ELISA with the 3 major antigens for AMA (namely, anti-MIT3), Sp100, and gp210 seemed to enhance the sensitivity and specificity for the diagnosis of isolated PBC28 or PBC-SSc overlap2. Nevertheless, the prognostic value of these autoantibodies detected by ELISA has not been established in PBC to date.

Anti-MIT3, anti-gp210, and Sp100 antibodies (the PBC screen) were found globally in 21.4% of our cohort of 201 unselected SSc cases, while anti-MIT3 antibodies were detected in 18% of cases. These autoantibodies have been described in SSc without clinical or biochemical signs of autoimmune liver disease28,29,30. Although the prevalence of PBC screen antibodies in our patients with SSc was similar to the prevalence reported by others2,29, a diagnosis of PBC was determined more frequently in our cohort. Indeed, PBC was diagnosed in 14% of PBC screen-positive patients and in only 1.3% of screen-negative patients (p = 0.0009). Among PBC screen antibodies, anti-MIT3 showed a high sensitivity (6/8; 75%) and specificity (85.4%) for the diagnosis of PBC, confirming previous reports2. By contrast, the occurrence of anti-Sp100 antibodies or anti-gp210 did not confer any additional value to anti-MIT3 for the diagnosis of PBC, probably because of the small number of positive sera samples in our cohort.

Analyzing the isotypes of anti-MIT3 antibodies, IgG+IgA anti-MIT3 showed a significant association with the diagnosis of PBC (p = 0.014) and AMA (p = 0.0035) compared with other groups. The occurrence of anti-MIT3 of the IgG and IgA isotypes, with no evidence of elevation of total circulating IgG or IgA levels, may be consistent with the immune system affinity maturation and class switching toward specific mitochondrial antigens rather than simple polyclonal B cell activation. Indeed, specific antipyruvate dehydrogenase complex IgA have been described in PBC, in circulation or localized in the apical surface and in the cytoplasm of biliary epithelial cells7. Moreover, AMA-IgA seems to possess a direct toxic effect on biliary epithelium31, contributing to the complex pathogenesis of bile duct damage in PBC7.

The occurrence of IgG+IgA anti-MIT3 antibodies was associated with persistent elevation of ALP in our series. High ALP value, along with increased bilirubin and reduced serum albumin, is considered a very sensitive indicator of disease severity, poor response to UDCA treatment, and progression to liver failure in PBC15,19,31,32. Some investigators have reported a significant association between ALP elevation and ACA or anti-topo-I antibodies, independent from AMA or anti-Sp100 status2. By contrast, presence of anti-RNAPIII antibodies was associated with lower ALP levels2. In our experience ALP elevation is associated with IgG+IgA anti-MIT3 antibodies, independent from ACA or anti-topo-I positivity.

Most of the AMA-positive sera samples (7/8) showed anti-MIT3 antibodies. Although time-consuming, the IIF assay using rodent tissue sections as substrate is considered the gold standard for detection of AMA33. This test showed a lower specificity and sensitivity compared with Western blot or ELISA tests34, with good performance when compared with the line immunoassay26.

The availability of fully automated ELISA testing could enhance investigation of various autoantibodies that are considered markers of PBC in routine laboratory analysis, avoiding the use of different assays with diversified antigen sources. In addition, given the specific association between PBC and IgG+IgA anti-MIT3, characterization of the isotype specificity could be helpful for more accurate assessment of patients. Further studies are needed to clarify the possible association between the development of PBC and the anti-MIT3 antibodies in IgG vs IgG+IgA classes.

  • Accepted for publication June 9, 2011.

REFERENCES

  1. 1.↵
    1. Avouac J,
    2. Airò P,
    3. Dieude P,
    4. Caramaschi P,
    5. Tiev K,
    6. Diot E,
    7. et al.
    Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients. J Rheumatol 2010;37:608–14.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Assassi S,
    2. Fritzler MJ,
    3. Arnett FC,
    4. Norman GL,
    5. Shah KR,
    6. Gourh P,
    7. et al.
    Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009;36:2250–6.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Rigamonti C,
    2. Shand LM,
    3. Feudjo M,
    4. Bunn CC,
    5. Black CM,
    6. Denton CP,
    7. et al.
    Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006;55:388–94.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kaplan MM,
    2. Gershwin ME
    . Primary biliary cirrhosis. N Engl J Med 2005;353:1261–73.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Gershwin ME,
    2. Ansari AA,
    3. MacKay IR,
    4. Nakanuma Y,
    5. Nishio A,
    6. Rowley MJ,
    7. et al.
    Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210–25.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Miyakawa H,
    2. Tanaka A,
    3. Kikuchi K,
    4. Matsushita M,
    5. Kitazawa E,
    6. Kawaguchi N,
    7. et al.
    Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001;34:243–8.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Selmi C,
    2. Zuin M,
    3. Bowleus CL,
    4. Gershwin ME
    . Anti-mitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis 2008;12:173–85.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Lleo A,
    2. Invernizzi P,
    3. Mackay IR,
    4. Prince H,
    5. Zhong RQ,
    6. Gershwin ME
    . Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008;14:3328–37.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Miyachi K,
    2. Hankins RW,
    3. Matsushima H,
    4. Kikuchi F,
    5. Inomata T,
    6. Horigome T,
    7. et al.
    Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 2003;20:247–54.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Itoh S,
    2. Ichida T,
    3. Yoshida T,
    4. Hayakawa A,
    5. Uchida M,
    6. Tashiro-Itoh T,
    7. et al.
    Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998;13:257–65.
    OpenUrlPubMed
  11. 11.↵
    1. Invernizzi P,
    2. Selmi C,
    3. Ranftler C,
    4. Podda M,
    5. Wesierska-Gadek J
    . Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005;25:298–310.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Moteki S,
    2. Leung PS,
    3. Coppel RL,
    4. Dickson ER,
    5. Kaplan MM,
    6. Munoz S,
    7. et al.
    Use of a designer triple expression hybrid clone for three different lipoyl domains for the detection of antimitochondrial autoantibodies. Hepatology 1996;24:97–103.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. LeRoy EC,
    2. Black C,
    3. Fleischmajer R,
    4. Jablonska S,
    5. Krieg T,
    6. Medsger TA Jr.,
    7. et al.
    Scleroderma (systemic sclerosis): classification subsets and pathogenesis. J Rheumatol 1988;15:202–5.
    OpenUrlPubMed
  15. 15.↵
    1. Valentini G,
    2. Medsger TA Jr.,
    3. Silman AJ,
    4. Bombardieri S
    , editors. The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 2003;21 Suppl 29:S1–S56.
    OpenUrl
  16. 16.↵
    EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237–67.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Dickson ER,
    2. Grambsch PM,
    3. Fleming TE,
    4. Fisher LD,
    5. Langworthy A
    . Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1–7.
    OpenUrlPubMed
  18. 18.↵
    1. Kim WR,
    2. Wiesner RH,
    3. Therneau TM,
    4. Poterucha JJ,
    5. Porayko MK,
    6. Evans RW,
    7. et al.
    Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998;28:33–8.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Corpechot C,
    2. Abenavoli L,
    3. Rabahi N,
    4. Chretiwn Y,
    5. Andreani T,
    6. Johanet C,
    7. et al.
    Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871–7.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Bernstein RM,
    2. Bunn CC,
    3. Hughes GRV
    . Identification of antibodies to acidic antigens by counterimmunoelectrophoresis. Ann Rheum Dis 1982;41:554–5.
    OpenUrlFREE Full Text
  21. 21.↵
    1. Clark G,
    2. Reichlin M,
    3. Tomasi TB
    . Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J Immunol 1969;102:117–22.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Venables PJW,
    2. Smith PR,
    3. Maini RN
    . Purification and characterization of the Sjögren’s syndrome A and B antigens. Clin Exp Immunol 1983;54:731–8.
    OpenUrlPubMed
  23. 23.↵
    1. Verheijen R,
    2. Wiik A,
    3. De Jong BAW,
    4. Hoier-Madsen M,
    5. Ullman S,
    6. Halberg P,
    7. et al.
    Screening for autoantibodies to the nucleolar U3-and Th(7-2) ribonucleoproteins in patients’ sera using antisense riboprobes. J Immunol Methods 1994;169:173–82.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. van Venrooij WJ,
    2. Zendman AJW,
    3. Pruijn GJM
    . Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006;6:37–41.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Arbuckle MR,
    2. McClain MT,
    3. Rubertone MV,
    4. Scofield RH,
    5. Dennis GJ,
    6. James JA,
    7. et al.
    Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Stinton LM,
    2. Swain M,
    3. Myers RP,
    4. Shaheen AA,
    5. Fritzler MJ
    . Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol 2010;163:147–56.
    OpenUrlPubMed
  27. 27.↵
    1. Favreau C,
    2. Bastos R,
    3. Cartaud J,
    4. Courvalin JC,
    5. Mustonen P
    . Biochemical characterization of nuclear pore complex protein gp210 oligomers. Eur J Biochem 2001;268:3883–9.
    OpenUrlPubMed
  28. 28.↵
    1. Dähnrich C,
    2. Pares A,
    3. Caballeria L,
    4. Rosemann A,
    5. Schlumberger W,
    6. Probst C,
    7. et al.
    New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009;55:978–85.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Norman GL,
    2. Bialek A,
    3. Ancabo S,
    4. Butkiewcz B,
    5. Wiechowska-Kozlowska A,
    6. Brzosko M,
    7. et al.
    Is prevalence of PBC underestimated in patients with systemic sclerosis? Dig Liver Dis 2009;41:762–4.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Mytilinaiou MG,
    2. Bogdanos DP
    . Primary biliary cirrhosis-specific autoantibodies in patients with systemic sclerosis. Dig Liver Dis 2009;41:914–7.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Matsumura S,
    2. van de Water J,
    3. Leung P,
    4. Odin JA,
    5. Yamamoto K,
    6. Gores JD,
    7. et al.
    Caspase induction by IgA antimitochondrial antibodies: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 2004;39:1415–22.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Hohenester S,
    2. Oude-Elferink RPJ,
    3. Beuers U
    . Primary biliary cirrhosis. Semin Immunopathol 2009;31:283–307.
    OpenUrlPubMed
  33. 33.↵
    1. Vergani D,
    2. Alvarez F,
    3. Bianchi FB,
    4. Cancado EL,
    5. Mackay IR,
    6. Manns MP,
    7. et al.
    Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41:677–83.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Muratori P,
    2. Muratori L,
    3. Gershwin ME,
    4. Czaja AJ,
    5. Pappas G,
    6. MacCariello S,
    7. et al.
    ‘True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol 2004;135:154–8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 10
1 Oct 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis
ILARIA CAVAZZANA, ANGELA CERIBELLI, MARA TARABORELLI, MICAELA FREDI, GARY NORMAN, ANGELA TINCANI, MINORU SATOH, FRANCO FRANCESCHINI
The Journal of Rheumatology Oct 2011, 38 (10) 2180-2185; DOI: 10.3899/jrheum.110167

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis
ILARIA CAVAZZANA, ANGELA CERIBELLI, MARA TARABORELLI, MICAELA FREDI, GARY NORMAN, ANGELA TINCANI, MINORU SATOH, FRANCO FRANCESCHINI
The Journal of Rheumatology Oct 2011, 38 (10) 2180-2185; DOI: 10.3899/jrheum.110167
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications
  • Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
  • Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire